MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Akero Therapeutics ROE Ratio 2011-2026 | AKRO
Annual ROE Ratio Akero Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -33.6 | -28.35 | -34.31 | -59.59 | -30.62 | -33.99 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -28.35 | -59.59 | -36.74 |
Quarterly ROE Ratio Akero Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.09 | -33.58 | -23.66 | -30.46 | -25.66 | -20.28 | -30.62 | -34.17 | -47.59 | -46.58 | -58.83 | -60.73 | -55.4 | -31.53 | -62.14 | -80.51 | -97.98 | -91.85 | -125.84 | -129.21 | -132.59 | -101.97 | -79.64 | -23.32 | 73.85 | 93.95 | 93.95 | 71.62 | 8.45 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 93.95 | -132.59 | -38.53 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.79 | -1.15 % | $ 4.31 M |  China |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.49 | 0.58 % | $ 1.04 B |  Canada |
 |
Frequency Therapeutics
FREQ
|
-227.96 | - | - | $ 528 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M | China |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.6 | 1.41 % | $ 8.66 B |  Australia |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Grifols, S.A.
GRFS
|
9.2 | $ 7.81 | -2.01 % | $ 6.83 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 225.98 | -1.32 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-138.5 | $ 4.13 | -5.06 % | $ 105 M |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
BioCardia
BCDA
|
721.83 | $ 1.26 | -0.79 % | $ 26.7 M | USA |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
|
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 14.2 | -0.7 % | $ 208 M | USA |
 |
Aptose Biosciences
APTO
|
559.76 | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 91.19 | 1.21 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.44 | -1.37 % | $ 367 M | Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 6.68 | -4.57 % | $ 183 M |  Israel |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
-116.29 | - | - | $ 521 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 7.92 | 1.67 % | $ 1.31 B | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.54 | -5.22 % | $ 16 M | USA |
 |
Certara
CERT
|
-0.15 | $ 6.67 | 1.6 % | $ 1.07 B | USA |
 |
Athira Pharma
ATHA
|
-216.19 | - | - | $ 269 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 3.6 | -4.0 % | $ 7.83 B | Israel |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
149.7 | - | -2.5 % | $ 5.88 M | USA |